# Table 6 — Summary of Findings (condensed for Results section)

**Certainty of evidence per outcome — GRADE assessment**

| Outcome | Pooled estimate (range) | № of SRs (≈ N) | Certainty | Importance |
|---|---|---|---|---|
| ypN0 overall | 37–40% (30–45%) | 12 (~88,000) | Moderate ⊕⊕⊕○ | Critical |
| ypN0 HR-/HER2+ | 65.7% (53–76%) | 6 (~12,000) | Moderate ⊕⊕⊕○ | Critical |
| ypN0 HR+/HER2- | 21.2% (14–31%) | 8 (~30,000) | Low ⊕⊕○○ | Critical |
| ypN0 TNBC (chemo-only / chemo-IO) | 48% / 67–86% | 7 (~15,000) | Low ⊕⊕○○ | Critical |
| FNR TAD vs SLNB | 1.4–4.2% vs 12.6% | 5 SRs + 4 trials (~4,500) | Moderate ⊕⊕⊕○ | Critical |
| 5-yr axillary recurrence (ALND-omission) | 1.0% (0.49–2.0%) | 4 SRs + Montagna 2024 (~1,500) | Low ⊕⊕○○ | Critical |
| 5-yr locoregional recurrence | 2.7% (1.5–4.5%) | 4 (~6,000) | Low ⊕⊕○○ | Important |
| OS benefit TAD vs ALND | No difference @ 36 mo | 2 (NR) | Very Low ⊕○○○ | Critical |

**Legend.** ⊕⊕⊕⊕ High; ⊕⊕⊕○ Moderate; ⊕⊕○○ Low; ⊕○○○ Very Low. Full per-outcome justification, downgrade/upgrade rationale, and contributing SRs are reported in Supplementary File **S7**.

